To investigate the efficacy of different doses of corticosteroids in treating severe coronavirus disease 2019 (COVID-19) pneumonia. Between May 01, 2023, and June 20, 2023, 48 patients with severe COVID-19 pneumonia were treated at the Department of Respiratory and Critical Care Medicine of Jinan Fourth People's Hospital. The observation group (21 patients) received standard care and high-dose corticosteroids, (high-dose group). The control group (27 patients) received standard care and low-dose corticosteroids (low-dose group). We collected baseline data and recorded inflammatory marker levels after 3 days of treatment, body temperature recovery time, length of stay, and 28-day all-cause mortality. The results of outpatient follow-up were recorded after 1 month. There were no significant differences in 28-day mortality and length of stay. The number of days it took for body temperature to return to normal in the high-dose group was less than in the low-dose group. The high-dose group had significantly more reduced inflammatory factors (C-reactive protein (CRP), interleukin-6 (IL-6). A total of 20 discharged patients were given 8–16 mg of methylprednisolone, depending on chest computed tomography (CT) and clinical symptoms after 1 month; in all discharged patients using oral corticosteroids, CT features improved. High-dose corticosteroids had a significantly positive effect on the reduction of inflammatory factors and shortening body temperature recovery time. In the treatment of severe COVID-19 pneumonia, early administration of high-dose, short-course corticosteroids should be implemented. The highlights of the paper are: 1. High-dose corticosteroid can shorten the recovery time of body temperature. 2. High-dose corticosteroid can better reduce inflammatory factors (CRP IL-6). 3. Oral hormones in discharged patients with severe COVID-19 pneumonia are beneficial. 4. Initial dosage and course of corticosteroid might be varied case by case.

中文翻译：

---

不同剂量皮质类固醇治疗重症COVID-19肺炎的疗效

探讨不同剂量皮质类固醇治疗2019冠状病毒病（COVID-19）重症肺炎的疗效。 2023年5月1日至2023年6月20日期间，济南市第四人民医院呼吸与危重症医学科收治了48名重症COVID-19肺炎患者。观察组（21名患者）接受标准护理和高剂量皮质类固醇（高剂量组）。对照组（27名患者）接受标准护理和低剂量皮质类固醇（低剂量组）。我们收集基线数据并记录治疗 3 天后的炎症标志物水平、体温恢复时间、住院时间和 28 天全因死亡率。 1个月后记录门诊随访结果。 28 天死亡率和住院时间没有显着差异。高剂量组体温恢复正常所需的天数少于低剂量组。高剂量组的炎症因子（C反应蛋白（CRP）、白细胞介素-6（IL-6））显着减少。根据胸部计算机断层扫描（胸部计算机断层扫描），总共 20 名出院患者接受了 8-16 毫克甲基泼尼松龙治疗（ CT）和1个月后的临床症状；所有出院患者使用口服皮质类固醇后，CT特征均有改善。大剂量皮质类固醇对于减少炎症因子、缩短体温恢复时间有显着的积极作用。在重症新冠肺炎的治疗中19肺炎，应实施早期大剂量、短疗程皮质类固醇给药，论文要点是：1.大剂量皮质类固醇可以缩短体温恢复时间2.大剂量皮质类固醇可以更好地减轻炎症因素（CRP IL-6）。 3. 对于出院的重症 COVID-19 肺炎患者，口服激素是有益的。 4. 皮质类固醇的初始剂量和疗程可能因具体情况而异。